Cargando…
Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors
Tumors arising in the context of Lynch Syndrome or constitutional mismatch repair deficiency are hypermutated and have a good response towards immune-checkpoint inhibitors (ICIs), including α-PD-L1 antibodies. However, in most cases, resistance mechanisms evolve. To improve outcomes and prevent resi...
Autores principales: | Salewski, Inken, Henne, Julia, Engster, Leonie, Schneider, Bjoern, Lemcke, Heiko, Skorska, Anna, Berlin, Peggy, Henze, Larissa, Junghanss, Christian, Maletzki, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199186/ https://www.ncbi.nlm.nih.gov/pubmed/34206051 http://dx.doi.org/10.3390/ijms22115990 |
Ejemplares similares
-
CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors
por: Salewski, Inken, et al.
Publicado: (2022) -
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors
por: Krone, Paula, et al.
Publicado: (2023) -
Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors
por: Salewski, Inken, et al.
Publicado: (2021) -
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells—A Systematic Analysis
por: Schoenwaelder, Nina, et al.
Publicado: (2021) -
Preclinical Head and Neck Squamous Cell Carcinoma Models for Combined Targeted Therapy Approaches
por: Schoenwaelder, Nina, et al.
Publicado: (2022)